Hyperphosphatemia Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight | Ardelyx, Shield Therapeutics, Kyowa Kirin Co., Ltd., Shanghai Alebund Pharma, Sanofi, Bayer, Keryx

The Key Hyperphosphatemia Companies in the market include - FRESENIUS MEDICAL CARE RENAL PHARMACEUTICALS, Astellas pharma, Unicycive Therapeutics, Ardelyx, Shield Therapeutics, Kyowa Kirin Co., Ltd., Shanghai Alebund Pharma, Sanofi, Bayer, Keryx Biopharma, Kissei Pharma, Taisho Pharma, Alebund Pharmaceuticals, Nabi Biopharma, Astellas Pharma Inc, Novartis, Sanofi, Mitsubishi Tanabe Pharma, and others.
DelveInsight's "Hyperphosphatemia Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Hyperphosphatemia, historical and forecasted epidemiology as well as the Hyperphosphatemia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Hyperphosphatemia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Hyperphosphatemia Market Forecast [https://www.delveinsight.com/sample-request/hyperphosphatemia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key facts of the Hyperphosphatemia Market Report:

*
The Hyperphosphatemia market size is anticipated to grow with a significant CAGR during the study period (2020-2034)

*
In September 2024, Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company focused on kidney disease treatments, announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Oxylanthanum Carbonate (OLC). The application seeks approval for OLC as a treatment for hyperphosphatemia in patients with chronic kidney disease (CKD) undergoing dialysis. The company is pursuing FDA approval through the 505(b)(2) regulatory pathway.

*
In 2023, the United States recorded the highest prevalence of Hyperphosphatemia in the 7MM, with approximately 500,000 cases.

*
In 2023, Germany had the highest prevalence of cases among the EU4 countries and the UK, with approximately 56,000 cases.

*
Japan reported the second-highest prevalence among the 7MM in 2023, with approximately 300,000 cases.

*
According to DelveInsight's estimates, the United States had approximately 2.4 million prevalent cases of CKD stages 3-5 in 2023.

*
The United States had the largest market size for Hyperphosphatemia in the 7MM, estimated at around USD 2,400 million.

*
In 2023, Germany made the largest market size contribution among the EU4 countries and the UK, totaling approximately USD 150 million.

*
Key Hyperphosphatemia Companies: FRESENIUS MEDICAL CARE RENAL PHARMACEUTICALS, Astellas pharma, Unicycive Therapeutics, Ardelyx, Shield Therapeutics, Kyowa Kirin Co., Ltd., Shanghai Alebund Pharma, Sanofi, Bayer, Keryx Biopharma, Kissei Pharma, Taisho Pharma, Alebund Pharmaceuticals, Nabi Biopharma, Astellas Pharma Inc, Novartis, Sanofi, Mitsubishi Tanabe Pharma, and others

*
Key Hyperphosphatemia Therapies: VELPHORO/P-TAL, KIKLIN, Oxylanthanum Carbonate (OLC), Ibsrela (tenapanor), PT20, KHK7791, Tenapanor, VS-505, Sevelamer Carbonate (GZ419831), Lanthanum Carbonate (BAY77-1931), Ferric Citrate, PA21, TS-172, AP-306, calcium acetate, ASP1585, SBR759A, Renvela Registered , MCI-196, and others

*
The Hyperphosphatemia epidemiology based on gender analyzed that Hyperphosphatemia occurs in both men and women

*
The Hyperphosphatemia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Hyperphosphatemia pipeline products will significantly revolutionize the Hyperphosphatemia market dynamics.

Hyperphosphatemia Overview

A rise in serum phosphate levels exceeding 4.5 mg/100 mL indicates the presence of hyperphosphatemia. In individuals with chronic kidney disease (CKD), the illness is typically brought on by a decline in renal function, which causes phosphate levels to rise unusually high.

Get a Free sample for the Hyperphosphatemia Market Report

https://www.delveinsight.com/report-store/hyperphosphatemia-market [https://www.delveinsight.com/report-store/hyperphosphatemia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Hyperphosphatemia Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Hyperphosphatemia Epidemiology Segmentation:

The Hyperphosphatemia market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:

*
Total Prevalence of Hyperphosphatemia

*
Prevalent Cases of Hyperphosphatemia by severity

*
Gender-specific Prevalence of Hyperphosphatemia

*
Diagnosed Cases of Episodic and Chronic Hyperphosphatemia

Download the report to understand which factors are driving Hyperphosphatemia epidemiology trends @ Hyperphosphatemia Epidemiology Forecast [https://www.delveinsight.com/sample-request/hyperphosphatemia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Hyperphosphatemia Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Hyperphosphatemia market or expected to get launched during the study period. The analysis covers Hyperphosphatemia market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Hyperphosphatemia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Hyperphosphatemia Therapies and Key Companies

*
VELPHORO/P-TAL: FRESENIUS MEDICAL CARE RENAL PHARMACEUTICALS

*
KIKLIN: Astellas pharma

*
Oxylanthanum Carbonate (OLC): Unicycive Therapeutics

*
Ibsrela (tenapanor): Ardelyx

*
PT20: Shield Therapeutics

*
KHK7791: Kyowa Kirin Co., Ltd.

*
Tenapanor: Ardelyx

*
VS-505: Shanghai Alebund Pharma

*
Sevelamer Carbonate (GZ419831): Sanofi

*
Lanthanum Carbonate (BAY77-1931): Bayer

*
Ferric Citrate: Keryx Biopharma

*
PA21: Kissei Pharma

*
TS-172: Taisho Pharma

*
AP-306: Alebund Pharmaceuticals

*
calcium acetate: Nabi Biopharmaceuticals

*
ASP1585: Astellas Pharma Inc

*
SBR759A: Novartis

*
Renvela Registered : Sanofi

*
MCI-196: Mitsubishi Tanabe Pharma

Discover more about therapies set to grab major Hyperphosphatemia market share @ Hyperphosphatemia Treatment Market [https://www.delveinsight.com/sample-request/hyperphosphatemia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Hyperphosphatemia Market Drivers

*
Promising pipeline activity with newer mechanism of actions

*
Upsurging research and development

*
Large target population

Hyperphosphatemia Market Barriers

*
Poor knowledge of phosphate levels in food and phosphate management

*
High economic burden

*
Gastrointestinal side effects

*
High market competition

*
Lack of epidemiology data

Scope of the Hyperphosphatemia Market Report

*
Study Period: 2020-2034

*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

*
Key Hyperphosphatemia Companies: FRESENIUS MEDICAL CARE RENAL PHARMACEUTICALS, Astellas pharma, Unicycive Therapeutics, VELPHORO/P-TAL, KIKLIN, Oxylanthanum Carbonate (OLC), Ardelyx, Shield Therapeutics, Kyowa Kirin Co., Ltd., Shanghai Alebund Pharma, Sanofi, Bayer, Keryx Biopharma, Kissei Pharma, Taisho Pharma, Alebund Pharmaceuticals, Nabi Biopharma, Astellas Pharma Inc, Novartis, Sanofi, Mitsubishi Tanabe Pharma, and others

*
Key Hyperphosphatemia Therapies: VELPHORO/P-TAL, KIKLIN, Oxylanthanum Carbonate (OLC), Ibsrela (tenapanor), PT20, KHK7791, Tenapanor, VS-505, Sevelamer Carbonate (GZ419831), Lanthanum Carbonate (BAY77-1931), Ferric Citrate, PA21, TS-172, AP-306, calcium acetate, ASP1585, SBR759A, Renvela Registered , MCI-196, and others

*
Hyperphosphatemia Therapeutic Assessment: Hyperphosphatemia current marketed and Hyperphosphatemia emerging therapies

*
Hyperphosphatemia Market Dynamics: Hyperphosphatemia market drivers and Hyperphosphatemia market barriers

*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

*
Hyperphosphatemia Unmet Needs, KOL's views, Analyst's views, Hyperphosphatemia Market Access and Reimbursement

To know more about Hyperphosphatemia companies working in the treatment market, visit @ Hyperphosphatemia Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/hyperphosphatemia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Hyperphosphatemia Market Report Introduction

2. Executive Summary for Hyperphosphatemia

3. SWOT analysis of Hyperphosphatemia

4. Hyperphosphatemia Patient Share (%) Overview at a Glance

5. Hyperphosphatemia Market Overview at a Glance

6. Hyperphosphatemia Disease Background and Overview

7. Hyperphosphatemia Epidemiology and Patient Population

8. Country-Specific Patient Population of Hyperphosphatemia

9. Hyperphosphatemia Current Treatment and Medical Practices

10. Hyperphosphatemia Unmet Needs

11. Hyperphosphatemia Emerging Therapies

12. Hyperphosphatemia Market Outlook

13. Country-Wise Hyperphosphatemia Market Analysis (2020-2034)

14. Hyperphosphatemia Market Access and Reimbursement of Therapies

15. Hyperphosphatemia Market Drivers

16. Hyperphosphatemia Market Barriers

17. Hyperphosphatemia Appendix

18. Hyperphosphatemia Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=hyperphosphatemia-market-forecasted-to-surge-in-coming-years-20242034-analysis-by-delveinsight-ardelyx-shield-therapeutics-kyowa-kirin-co-ltd-shanghai-alebund-pharma-sanofi-bayer-keryx]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.